CSL Limited
CSL.AX
Get informed when a big investor buys or sells
+ FollowMarket Cap$118.26B
Close$
Share Statistics
| Market cap | $118.26 Billion |
|---|---|
| Enterprise Value | $127.64 Billion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 3.04% |
|---|---|
| Return on Assets | 1.34% |
| Return on Invested Capital | 28.99% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.09 |
| Enterprise Value to EBIT | 15.56 |
| Enterprise Value to Net Income | 283 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.74 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About CSL Ltd.
29,000 employees
CEO: Paul Perreault CSL Limited is a global biopharmaceutical enterprise engaged in the discovery, development, production, marketing, and distribution of a wide array of medicinal and related products. Its operations span key markets including Australia, t...